Myovant Sciences Ltd (MYOV) Expected to Post Earnings of -$0.95 Per Share

Share on StockTwits

Analysts forecast that Myovant Sciences Ltd (NYSE:MYOV) will report earnings of ($0.95) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Myovant Sciences’ earnings. The lowest EPS estimate is ($0.98) and the highest is ($0.92). Myovant Sciences reported earnings per share of ($0.70) in the same quarter last year, which indicates a negative year-over-year growth rate of 35.7%. The firm is scheduled to announce its next earnings report on Tuesday, February 12th.

On average, analysts expect that Myovant Sciences will report full-year earnings of ($3.91) per share for the current fiscal year, with EPS estimates ranging from ($4.00) to ($3.80). For the next financial year, analysts forecast that the firm will post earnings of ($3.82) per share, with EPS estimates ranging from ($4.34) to ($3.38). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last announced its earnings results on Thursday, November 8th. The company reported ($0.99) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.06).

A number of research firms recently weighed in on MYOV. Cowen reiterated a “buy” rating on shares of Myovant Sciences in a research report on Friday. Zacks Investment Research lowered Myovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 17th. JPMorgan Chase & Co. began coverage on Myovant Sciences in a research report on Thursday, September 13th. They issued an “overweight” rating and a $39.00 price target for the company. Finally, Goldman Sachs Group began coverage on Myovant Sciences in a research report on Friday, October 26th. They issued a “neutral” rating and a $25.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $29.20.

In related news, Director Mark Altmeyer purchased 3,500 shares of the firm’s stock in a transaction that occurred on Saturday, November 17th. The stock was acquired at an average price of $13.38 per share, for a total transaction of $46,830.00. Following the transaction, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $46,830. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Opera Trading Capital acquired a new position in shares of Myovant Sciences in the 3rd quarter valued at $117,000. JPMorgan Chase & Co. boosted its position in shares of Myovant Sciences by 6.2% in the 1st quarter. JPMorgan Chase & Co. now owns 106,944 shares of the company’s stock valued at $2,275,000 after purchasing an additional 6,263 shares during the period. Atria Investments LLC acquired a new position in shares of Myovant Sciences in the 3rd quarter valued at $201,000. Renaissance Technologies LLC acquired a new stake in Myovant Sciences during the 2nd quarter worth about $297,000. Finally, Matisse Capital acquired a new stake in Myovant Sciences during the 2nd quarter worth about $349,000. Institutional investors and hedge funds own 21.04% of the company’s stock.

Shares of MYOV stock opened at $19.06 on Wednesday. Myovant Sciences has a fifty-two week low of $11.30 and a fifty-two week high of $27.45. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.73.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

See Also: Preferred Stock

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply